A Cardiologist's Perspective on Cardiometabolic Risk

American Journal of Cardiology

Volumn 100, Issue 12 SUPPL. 1, 2007, Pages

  Plutzky, Jorge ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; ATHEROSCLEROSIS; CARDIOLOGIST; CARDIOMETABOLIC RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; EDUCATION PROGRAM; HUMAN; INTERVENTION STUDY; METABOLIC SYNDROME X; OBESITY; PRIORITY JOURNAL;

ADIPOSITY; ATHEROSCLEROSIS; CHOLESTEROL; HUMANS; METABOLIC SYNDROME X; PREVALENCE; RISK FACTORS; UNITED STATES;

EID: 37249009708     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2007.10.008     Document Type: Article

References (31)

1. Milani R.V., and Lavie C.J. Prevalence and profile of metabolic syndrome in patients following acute coronary events and effects of therapeutic lifestyle change with cardiac rehabilitation. Am J Cardiol 92 (2003) 50-54
2. Savage P.D., Banzer J.A., Balady G.J., and Ades P.A. Prevalence of metabolic syndrome in cardiac rehabilitation/secondary prevention programs. Am Heart J 149 (2005) 627-631
3. Kahn R., Buse J., Ferrannini E., Stern M., and American Diabetes Association and the European Association for the Study of Diabetes. The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 28 (2005) 2289-2304
4. Grundy S.M. Does the metabolic syndrome exist?. Diabetes Care 29 (2006) 1689-1692 discussion 1693-1696
5. Smith S.C., Allen J., Blair S.N., Bonow R.O., Brass L.M., Fonarow G.C., Grundy S.M., Hiratzka L., Jones D., Krumholz H.M., Mosca L., Pasternak R.C., Pearson T., Pfeffer M.A., Taubert K.A., AHA/ACC, and the National Heart, Lung, and and Blood Institute. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update. Endorsed by the National Heart, Lung, and Blood Institute. Circulation 113 (2006) 2363-2372
6. Cannon C.P., Braunwald E., McCabe C.H., Rader D.J., Rouleau J.L., Belder R., Joyal S.V., Hill K.A., Pfeffer M.A., Skene A.M., and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350 (2004) 1495-1504
7. Strong J.P., Malcom G.T., and Oalmann M.C. Environmental and genetic risk factors in early human atherogenesis: lessons from the PDAY [Pathobiological Determinants of Atherosclerosis in Youth] study. Pathol Int 45 (1995) 403-408
8. Tuzcu E.M., Kapadia S.R., Tutar E., Ziada K.M., Hobbs R.E., McCarthy P.M., Young J.B., and Nissen S.E. High prevalence of coronary atherosclerosis in asymptomatic teenagers and young adults: evidence from intravascular ultrasound. Circulation 103 (2001) 2705-2710
9. Kramer D., Raji A., and Plutzky J. Prediabetes mellitus and its links to atherosclerosis. Curr Diabetes Rep 3 (2003) 11-18
10. Nathan D.M., Davidson M.B., DeFronzo R.A., Heine R.J., Henry R.R., Pratley R., Zinman B., and American Diabetes Association. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care 30 (2007) 753-759
11. Kramer R.M., Stephenson D.T., Roberts E.F., and Clemens J.A. Cytosolic phospholipase A2 (cPLA2) and lipid mediator release in the brain. J Lipid Mediat Cell Signal 14 (1996) 3-7
12. Karasik A. Glycaemic control is essential for effective cardiovascular risk reduction across the type 2 diabetes continuum. Ann Med 37 (2005) 250-258
13. Haffner S.M., Stern M.P., Hazuda H.P., Mitchell B.D., and Patterson J.K. Cardiovascular risk factors in confirmed prediabetic individuals: does the clock for coronary heart disease start ticking before the onset of clinical diabetes?. JAMA 263 (1990) 2893-2898
14. Grundy S.M., Cleeman J.I., Daniels S.R., Donato K.A., Eckel R.H., Franklin B.A., Gordon D.J., Krauss R.M., Savage P.J., Smith S.C., Spertus J.A., Costa F., American Heart Association and the National Heart, Lung, and and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112 (2005) 2735-2752
15. Norhammar A., Tenerz A., Nilsson G., Hamsten A., Efendic S., Ryden L., and Malmberg K. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet 359 (2002) 2140-2144
16. Matz K., Keresztes K., Tatschl C., Nowotny M., Dachenhausenm A., Brainin M., and Tuomilehto J. Disorders of glucose metabolism in acute stroke patients: an underrecognized problem. Diabetes Care 29 (2006) 792-797
17. Brunner E.J., Shipley M.J., Witte D.R., Fuller J.H., and Marmot M.G. Relation between blood glucose and coronary mortality over 33 years in the Whitehall Study. Diabetes Care 29 (2006) 26-31
18. Kahn B.B., and Pedersen O. Suppression of GLUT4 expression in skeletal muscle of rats that are obese from high fat feeding but not from high carbohydrate feeding or genetic obesity. Endocrinology 132 (1993) 13-22
19. Knowler W.C., Barrett-Connor E., Fowler S.E., Hamman R.F., Lachin J.M., Walker E.A., Nathan D.M., and Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346 (2002) 393-403
20. DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 368 (2006) 1096-1105 [published correction appears in Lancet 2006;368:1770]
21. Maison P., Byrne C.D., Hales C.N., Day N.E., and Wareham N.J. Do different dimensions of the metabolic syndrome change together over time?. Evidence supporting obesity as the central feature. Diabetes Care 24 (2001) 1758-1763
22. Larsson B., Svardsudd K., Welin L., Wilhelmsen L., Bjorntorp P., and Tibblin G. Abdominal adipose tissue distribution, obesity, and risk of cardiovascular disease and death: 13 year follow up of participants in the study of men born in 1913. BMJ 288 (1984) 1401-1404
23. Terry R.B., Page W.F., and Haskell W.L. Waist/hip ratio, body mass index and premature cardiovascular disease mortality in US Army veterans during a twenty-three year follow-up study. Int J Obes Relat Metab Disord 16 (1992) 417-423
24. Rimm E.B., Stampfer M.J., Giovannucci E., Ascherio A., Spiegelman D., Colditz G.A., and Willett W.C. Body size and fat distribution as predictors of coronary heart disease among middle-aged and older US men. Am J Epidemiol 141 (1995) 1117-1127
25. Rexrode K.M., Carey V.J., Hennekens C.H., Walters E.E., Colditz G.A., Stampfer M.J., Willett W.C., and Manson J.E. Abdominal adiposity and coronary heart disease in women. JAMA 280 (1998) 1843-1848
26. Yusuf S., Hawken S., Ounpuu S., Dans T., Avezum A., Lanas F., McQueen M., Budaj A., Pais P., Varigos J., Lisheng L., and INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364 (2004) 937-952
27. Poirier P., Giles T.D., Bray G.A., Hong Y., Stern J.S., Pi-Sunyer F.X., and Eckel R.H. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss. Arterioscler Thromb Vasc Biol 26 (2006) 968-976
28. Lee M., and Aronne L.J. Weight management for type 2 diabetes mellitus: global cardiovascular risk reduction. Am J Cardiol 99 suppl (2007) 68B-79B
29. Stannard S.R., and Johnson N.A. Insulin resistance and elevated triglyceride in muscle: more important for survival than "thrifty" genes?. J Physiol 554 (2004) 595-607
30. Bergman R.N., Kim S.P., Hsu I.R., Catalano K.J., Chiu J.D., Kabir M., Richey J.M., and Ader M. Abdominal obesity: role in the pathophysiology of metabolic disease and cardiovascular risk. Am J Med 120 suppl 1 (2007) S3-S8 discussion S29-S32
31. Cannon P., Yang X., Szabolcs M.J., Ravalli S., Sciacca R.R., and Michler R.E. The role of inducible nitric oxide synthase in cardiac allograft rejection. Cardiovasc Res 38 (1998) 6-15